AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- ResMed (RMD) gains over 5% in 2025 YTD.
- Strong global footprint and dual growth in medical tech and SaaS.
- Healthcare's consistent revenue and ESG relevance supports interest.
ResMed (ASX:RMD), a global medical technology company, has seen its share price rise by 5.2% since the beginning of 2025. With its dual presence on both the ASX and NYSE, and its continued innovation in respiratory care and software solutions, the company is steadily making waves in the ASX200 stocks category.
Innovative Healthcare Technology
ResMed, originally founded in Australia and now headquartered in San Diego, develops and distributes cloud-connected devices that treat obstructive sleep apnea (OSA). These devices, particularly its CPAP (Continuous Positive Airway Pressure) machines, have established ResMed as a global leader in the sleep and respiratory care space. Alongside this, ResMed also operates a robust Software as a Service (SaaS) division that supports durable and home medical equipment with digital tools for improved patient care.
With over 10,000 employees and operations across 140 countries, ResMed is well-positioned to benefit from global healthcare trends. The integration of data from its devices into its SaaS offerings provides actionable insights, supporting better patient outcomes and cost-effective care.
Healthcare: A Defensive and Ethical Sector
The broader S&P/ASX200 Healthcare Index (ASX:XHJ) has delivered marginal returns over the past five years, but healthcare remains a resilient sector. Unlike commodity-based or cyclical industries, healthcare services represent essential spending. This resilience is often referred to as “sticky revenue,” as patients and providers continue to prioritize health-related expenses, even in uncertain economic conditions.
In terms of growth, global healthcare expenditure—particularly in the United States, which contributes over 40% of the total—is expected to expand steadily. Segments like healthcare IT and SaaS are forecast to grow at more than 15% annually through 2030, presenting considerable opportunities for companies like ResMed.
Furthermore, ethical investing is on the rise, with sectors offering social value, such as healthcare, attracting increased interest. The trend toward sustainable investment aligns with the broader mission of companies in this space to provide critical and life-enhancing services.
Valuation Snapshot
ResMed (ASX:RMD) is currently trading at a price-to-sales ratio of 5.24x, below its five-year average of 8.70x. This could reflect a stronger revenue base or previous share price adjustments. Over the past three years, the company has consistently grown its top-line revenue, which may make its current valuation worth a closer look, especially when viewed in the context of historical trends.
With a strong business model, global presence, and consistent innovation, ResMed continues to draw attention among ASX200 healthcare stocks. Its position at the intersection of medical technology and SaaS gives it a unique edge in a growing and increasingly tech-integrated sector.
